We are Healthy
U.S.

Phathom Pharmaceuticals Initiated Phase 3 NERD Drug Study

The clinical trial will evaluate an as-needed heartburn treatment for adults living with non-erosive GERD.

Updated on Sept. 29, 2026 in Diseases — General

Isometric editorial illustration of a glass beaker on a sterile lab surface, representing clinical pharmaceutical research.
Phathom Pharmaceuticals has launched a Phase 3 study to evaluate whether VOQUEZNA can serve as an effective as-needed treatment for non-erosive GERD. AI Illustration. Upload story photo >

Live Poll

Would you prefer using an as-needed medication for heartburn over taking a daily preventive pill?

Phathom Pharmaceuticals has begun patient screening for a Phase 3 study testing the efficacy of a 10 mg dose of VOQUEZNA for managing non-erosive gastroesophageal reflux disease (NERD). This clinical trial aims to support a potential label expansion for the medication as an as-needed treatment option.

Why it matters

With an estimated 15 million Americans currently living with non-erosive GERD, physicians and patients are seeking alternatives to daily medication. This study addresses that demand by investigating whether a flexible, symptom-driven approach can effectively manage chronic heartburn.

The Phase 3 trial, known as pHalcon-NERD-302, is designed as a 24-week study comparing 10 mg of VOQUEZNA against a placebo. This research follows a four-week open-label run-in period to confirm participant eligibility, with 500 adults across 80 U.S. sites currently being screened.

The players

Phathom Pharmaceuticals

A biopharmaceutical company based in Florham Park, N.J., that develops treatments for acid-related gastrointestinal disorders.

The details

The study utilizes a randomized, placebo-controlled design to measure whether VOQUEZNA can function as a demand-based therapy. Participants first undergo a four-week stabilization period using 10 mg daily; only those who report no heartburn during the final week of that run-in period advance to the study. Once randomized, the trial evaluates if the medication provides symptomatic relief when patients experience acid reflux flare-ups.

Timeline

  1. September 29, 2026: Patient screening began for the pHalcon-NERD-302 Phase 3 study.

  2. Q1 2028: Topline results from the trial are expected.

Health Landscape

This research follows a growing shift in gastroenterology toward flexible, patient-directed dosing regimens for acid-related disorders. It builds on the current standard of care by testing if an established treatment can be adapted to meet the specific demand for as-needed heartburn relief.

If you experience frequent heartburn, you may want to discuss the current options for as-needed versus daily GERD management with your physician. While this specific trial is in progress, your doctor can advise on whether your current symptom patterns align with emerging treatment strategies.

The takeaway

Ongoing research is currently exploring whether as-needed dosing can offer relief for the millions of Americans managing non-erosive GERD. If you struggle with chronic heartburn, consult your physician to track your symptom frequency and discuss whether current or future treatment options fit your needs.

Further reading

For more background on the latest developments in gastrointestinal health, explore our Diseases — General section.

More information

Find ongoing study details by searching the clinical trials registry search.

Live Poll

Would you prefer using an as-needed medication for heartburn over taking a daily preventive pill?